Physical Activity and Health-Related Quality of Life in Women With Breast Cancer: A Meta-Analysis

Dagfinn Aune, PhD,1,2,3,4† Georgios Markozannes, PhD,3,5,† Leila Abar, MSc,1 Katia Balducci, MSc,1 Margarita Carolou, MSc,1 Neesha Nanu, MSc,1 Rita Vieira, MSc,1 Yusuf O. Anifowoshe, MSc,1 Darren C. Greenwood, PhD,6 Steven K. Clinton, MD7,8 Edward L. Giovannucci, MD,9,10,11 Marc J. Gunter, PhD,12 Alan Jackson, MD,13 Ellen Kampman, PhD14 Vivien Lund, PhD,15 Anne McTiernan, MD, PhD,16,17,18 Edward L. Giovannucci, MD,14 Vivien Lund, PhD,15 Anne McTiernan, MD, PhD,16,17,18

†Joint first authors.

*Correspondence to: Doris S. M. Chan, PhD, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St Mary’s Campus, Norfolk Place, Paddington, London W2 1PG, UK (e-mail: d.chan@imperial.ac.uk).

Abstract

Background: Physical activity (PA) is associated with improved health-related quality of life (HRQoL) among women with breast cancer; however, uncertainty remains regarding PA types and dose (frequency, duration, intensity) and various HRQoL measures. A systematic review and meta-analysis of randomized controlled trials was conducted to clarify whether specific types and doses of physical activity was related to global and specific domains of HRQoL, as part of the Global Cancer Update Programme.

Methods: PubMed and CENTRAL databases were searched up to August 31, 2019. Weighted mean differences (WMDs) in HRQoL scores were estimated using random effects models. An independent expert panel graded the evidence.

Results: A total of 79 randomized controlled trials (14 554 breast cancer patients) were included. PA interventions resulted in higher HRQoL scores were estimated using random effects models. An independent expert panel graded the evidence.

Conclusion: PA results in improved global HRQoL in breast cancer.
Since 1949, the World Health Organization has noted that health is “a state of complete physical, mental, and social well-being and not merely the absence of disease” (1). In ensuing years, health-related quality of life (HRQoL) emerged as a relevant outcome, and among populations with cancer, it is a powerful predictor of mortality and morbidity (2,3). Thus, integrating the assessment of HRQoL into cancer clinical trials is critical and may provide greater insight into relevant outcomes beyond tumor response and survival (4).

Lifestyle factors, such as physical activity, are hypothesized to influence HRQoL in breast cancer patients. Several randomized controlled trials (RCTs) have reported beneficial effects of physical activity during or after adjuvant therapy on HRQoL after breast cancer (5-8) and other cancers (9,10) with little evidence of adverse effects. The benefits include improvement in specific symptoms such as fatigue (5,6), secondary lymphedema (11), physical function (12,13), emotional function and mental health (14,15), and global HRQoL (13,15,16). However, the available trials have often had small sample sizes and have in some cases failed to show clinically meaningful effects. In addition, different instruments that measure various aspects of HRQoL have been employed to measure quality of life (QoL) components, which could contribute toward heterogeneity in results between studies. For instance, the Functional Assessment of Cancer Therapy–General (FACT-G) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) have greater emphasis on cancer-related symptoms and less on physical functioning compared with the Short Form Health Survey (SF-36) (17). Clarifying whether the impact of physical activity varies by the instrument used to measure HRQoL could be important. In addition, various types of physical activity interventions have been tested across different studies including aerobic exercise, resistance exercise, aerobic and resistance exercise combined, walking, yoga, stretching, Tai chi, and Qigong. Additional research clarifying whether physical activity overall or specific types and combinations of physical activity are particularly beneficial for improving HRQoL in breast cancer patients is necessary to develop better physical activity recommendations for this patient group. Therefore, we conducted a systematic literature review and meta-analysis of physical activity and HRQoL as part of the Global Cancer Update Programme (CUP Global), previously known as the World Cancer Research Fund–American Institute for Cancer Research (WCRF-AICR) Continuous Update Project (https://www.wcrf.org/int/continuous-update-project).

The aims of this review and meta-analysis were to assess the existing evidence on whether physical activity improves global as well as physical, emotional, and mental domains of HRQoL measured by several common instruments; whether specific types of physical activity are particularly effective; and whether other aspects of interventions, such as the timing of the intervention (during or after primary treatment) or mode of intervention (group-based, individual-based, mixed), affected the results.

Methods

Search Strategy

PubMed and CENTRAL databases were searched up to August 31, 2019, for RCTs of physical activity and HRQoL among female breast cancer survivors. The search strategy is described in detail in the Supplementary Materials (Supplementary Text 1 and 2, available online) and included search terms for diet and body fatness as part of a larger ongoing project in the CUP Global. The database searches were supplemented by hand searches of the reference lists of the included studies and previous systematic reviews and meta-analyses on the topic. A peer-reviewed protocol was prepared before the review was conducted and is available online (18). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline for the reporting of systematic reviews and meta-analyses was followed (19).

Study Selection

We included peer-reviewed RCTs of physical activity and exercise before, during, or after primary treatment (defined as any surgical treatment and/or [neo]adjuvant therapy, including chemotherapy, radiotherapy, and/or hormonal therapy, in the acute phase of cancer diagnosis and treatment, but excluding extended use of hormonal therapy that may last years after diagnosis) and HRQoL overall and its main functional domains (physical, emotional, or mental) measured using validated tools to assess HRQoL, among women who had been diagnosed with breast cancer as first cancer during adulthood, at any stage of diagnosis. For the current analysis, exclusion criteria were 1) nonrandomized clinical trials, quasi-randomized trials, 1-arm pre-posttest design studies, population-level studies, cohort studies, cross-sectional studies, case-control studies, retrospective studies; 2) studies in which the comparison group is not from the same study population; 3) studies of exposures other than physical activity; 4) multimodal or combined interventions where the effect of the physical activity intervention could not be separated from other interventions; 5) HRQoL outcomes not reported; 6) comments, reviews, news, and conference abstracts; 7) studies with mixed cancer sites where breast cancer was not evaluated separately; and 8) studies with less than 20 participants.

Data Extraction

The following information was extracted: author; publication year; title; study design and type (parallel, factorial, crossover, other); study name; number of study centers; study period; country; study participant characteristics (age, race and ethnicity); menopausal status at cancer diagnosis; body mass index; smoking status; comorbidities (eg, hypertension, cardiovascular disease, and diabetes mellitus); other specific characteristics (BRCA1 and BRCA2 mutation carriers); disease characteristics (ductal carcinoma in situ, invasive, local, regional, distant, or metastatic breast cancer; tumor, node, and metastases classification; grade; other stage; molecular characteristics); year of breast cancer diagnosis; time since breast cancer diagnosis; breast cancer treatment (surgery, radiation, chemotherapy, hormone therapy) and modality (neo/adjuvant, adjuvant, palliative); interventions (modality, frequency, intensity, duration of intervention); number of participants allocated to each arm; randomization method; allocation method; method for assessment
of HRQoL; means (per arm) or mean differences (between arms); standard deviations or standard errors; confidence intervals (CIs); P values; and analysis (intention to treat or per protocol).

Risk of Bias Assessment

Risk of bias was assessed using the Revised Cochrane Risk-of-Bias tool for Randomized trials (20). The tool assesses the risk of bias of RCTs based on several signaling questions on 1) bias arising from the random assignment process, 2) bias because of deviations from intended interventions, 3) bias because of missing outcome data, 4) bias in measurement of the outcome, and 5) bias in selection of the reported result. The HRQoL assessment was considered unlikely to be influenced by knowledge of intervention received when the patient-reported HRQoL measures showed an effect in the same direction (or null effect) as the objective physical or cognitive performance measures in the studies. For each domain, risk of bias was graded as 1) low, 2) with some concerns, or 3) high, and an overall assessment across items was made as well.

Evidence Grading

An independent WCRF-AICR expert panel graded the evidence by its strength and likelihood of causality into strong (subgrades evaluating likelihood of causality: convincing or probable) or limited (subgrades evaluating likelihood of causality: limited suggestive or limited no conclusion) level. Predefined grading criteria were used to assess study design; risk of bias; the quantity, consistency, magnitude, and precision of the effect estimates; existence of a dose response; and the generalizability and mechanistic plausibility of the results (Supplementary Table 2, available online).

Statistical Methods

Inverse variance DerSimonian-Laird random effects models were used to calculate summary weighted mean differences (WMDs), weighted mean change differences (WMCDs), and standardized mean differences (SMDs) (95% CIs) for participants who were randomly assigned to physical activity interventions compared with those randomly assigned to a control group (21). We were interested in the effect of assignment to intervention (the intention-to-treat effect) but used the results from the per-protocol analysis if this was the only analysis conducted in the studies. Final HRQoL and change from baseline measures were analyzed separately because the baseline values may be different in the intervention and control groups. Separate analyses were conducted for each HRQoL instrument, including the cancer-specific measures EORTC QLQ-C30, FACT-G, with its breast cancer-specific subscale (FACT-B) or fatigue subscale (Functional Assessment of Chronic Illness Therapy–Fatigue [FACT-F]), because of different constructs in their scales and subscales. A list of items included in the instruments is shown in Table 1, and effect sizes of minimum clinical importance by HRQoL scale are shown in Supplementary Table 1 (available online). Exceptions were made when the instruments were similar and could be combined (eg, the generic measures Medical Outcomes Study–36-item short-form [MOS SF-36] and RAND SF-36 for the analysis of general health perceptions). The meta-analysis included analyses of global HRQoL scores (FACT-B, FACT-G, EORTC QLQ-C30), general health perceptions (MOS SF-36, RAND SF-36), physical well-being (FACT-T, FACT-B, FACT-G, physical functioning (EORTC QLQ-C30, MOS SF-36, RAND SF-36), physical component summary score (MOS SF-36), emotional well-being functioning (FACT-T, FACT-B, FACT-G), emotional functioning (EORTC QLQ-C30), mental health score (MOS SF-36, RAND SF-36), and mental component summary score (MOS SF-36). Across all instruments, WMDs, WMCDs, and SMDs statistically significant results above 0 indicate beneficial effects of the physical activity intervention, whereas statistically significant results below 0 indicate adverse effects. The main analysis was performed on the HRQoL measures from the final assessment (maximal follow-up). These values and their measures of variability such as standard deviations, confidence intervals, and number of participants per group were required to calculate the effect estimates. Missing data were imputed when possible following standard approaches (22). We did not use an external estimate of standard deviation or a correlation coefficient to impute missing standard deviations for the mean changes, to avoid making unjustifiable assumptions. When there was more than 1 exercise group in the RCT and when the raw data per group (eg, means, standard deviations, and number of participants) were available, we pooled the means from each arm using standardized formulas (22). If only the effect sizes were available, we pooled those using a fixed effects model before including the study in the overall analysis. For studies with a crossover design, we used the data from the start of the intervention until the time point where the second (delayed intervention) group started the crossover, so the second (delayed intervention) group served as a control group as they had not yet received the intervention (equivalent to a parallel design trial). Heterogeneity between studies was evaluated using Q and I² statistics (23). Subgroup and meta-regression analyses were conducted to investigate potential sources of heterogeneity and were stratified by type of exercise (aerobic and resistance exercise, aerobic exercise, resistance exercise, yoga, others), frequency (1-3 or >3 days per week), duration per session (<60 or >60 minutes per session), and total duration (<120, 120-180, or >180 minutes per week), as well as timing (during or after primary adjuvant treatment), mode of intervention (group based, individual based, mixed), and type of control group (attention control, others such as usual care, waiting list controls). Other subgroups by study or patient characteristics were generally small in numbers and not analyzed. Sensitivity analyses were conducted by estimating mean differences at postintervention or follow-up immediately after intervention (minimum follow-up) and by calculating SMDs as the same HRQoL assessment tools may differ slightly between the versions. Small study effects, such as publication bias, were assessed using Egger regression asymmetry test (24) and by visual inspection of the funnel plots, when there were 10 or more studies in the analysis. All statistical tests were 2-sided. The statistical analyses were conducted using the software package Stata, version 13.0 (StataCorp, TX, USA).

Results

Study Selection and Study Characteristics

From a total of 6101 records that were identified by the search (PubMed, CENTRAL, and handsearching), a total of 79 RCTs (92 publications) (12-16,25-111) were included in the systematic review (Figure 1; Supplementary Table 3, available online). Of these, 59 publications were included in the meta-analyses (12-16,25,27,31,33-38,43-47,49-52,54,56,58-60,64-67,69,74,75,79,81,83-
Table 1. List of items in the global, physical, and emotional domains of the health-related quality of life instruments

| Instrument | FACT-G | EORTC QLQ-C30 | SF-36 (MOS/RAND) |
|------------|--------|---------------|------------------|
| Domain     | Version 4.0 | Version 3.0 | 36 items, 8 domains |
|            | 27 items, 4 domains | 30 items, 9 domains, 6 single items | 3-, 5-, and 6-point Likert rating scale |
|            | 5-point Likert rating scale | 4- and 7-point Likert rating scale | Score range for each domain 0-100 |
|            | Total score range 0-108 | Score range for each domain 0-100 | Higher scores—better QoL |
| Physical well-being and function | Physical well-being (7 items, score range 0-28) | Physical functioning (5 items, score range 0-100) | Physical component scale |
|            | Physical symptoms: Have nausea | Strenuous activities | (10 items, score range 0-100) |
|            | Have pain | Short walk | Vigorous activities |
|            | Bothered by side effects of treatment | Long walk | Moderate activities |
|            | Impact: Trouble meeting the needs of family | Stay in bed or chair during the day | Lifting or carrying groceries |
|            | Lack of energy | Help with eating, dressing, washing yourself, or using toilet | Physical functioning |
|            | Feel ill | Bending, kneeling, or stooping | Physical role limitations |
|            | Spend time in bed | Walking more than 1 mile | Pain |
| Emotional well-being, function and mental health | Emotional well-being (6 items, score range 0-24) | Emotional functioning (4 items, score range 0-100) | Mental component scale |
|            | Feel sad | Felt tense | (5 items, score range 0-100) |
|            | Coping with illness | Worry | (4 scales, 14 items, score range 0-100) |
|            | Losing hope in the fight against illness | Felt irritable | Mental health |
|            | Feel nervous | Felt depressed | Felt down in the dumps |
|            | Worry about dying | | Felt calm and peaceful |
|            | Worry that condition will get worse | | Felt downhearted and blue |
| Global, total score, and general health | Total FACT-G: sum of all items (physical, emotional, functional, and social and family well-being) (27 items, score range 0-108) | Global QoL (2 items, score range 0-100) | General health |
|            | Total FACT-B: sum of all items in FACT-G and B (37 items, score range 0-148) | Self-rated overall health | (5 items, score range 0-100): Self-perceived health in general |
|            | Total FACT-B-4: sum of all items in FACT-G and B-4 (41 items, score range 0-148) | Self-rated overall QoL | More easily get sick than others |
|            | | | Healthy as other |
|            | | | Expect health to get worse |
|            | | | Excellent health |

*FACT-G: functional well-being (7 items, score range 0-28): able to work and is fulfilling; enjoy life and enjoy things for fun; accepted illness; sleep well; content with quality of life; EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–C30; FACT-B = Functional Assessment of Cancer Therapy–General and Breast cancer; FACT-B + 4 = Functional Assessment of Cancer Therapy for Breast Cancer + 4; FACT-G = Functional Assessment of Cancer Therapy–General; QoL = quality of life; SF-36 (MOS/RAND) = Short Form-36 (Medical Outcomes Study/RAND).*
6101 records identified in total for which title and abstract were reviewed
5992 records identified through PubMed
100 records identified through CENTRAL
9 records identified through handsearching

4485 records excluded based on title and abstract

1616 full-text publications assessed for eligibility

1324 publications excluded:
539 not relevant topic
184 reviews
153 study protocols
150 cross-sectional studies
88 non-RCTs/quasi-RCTs/one-arm pre-posttest design
57 studies of mixed cancer patients
49 meta-analyses
29 commentary/news
28 studies of not relevant outcomes
18 studies with <20 cancer survivors
13 case-control studies
8 case reports
8 foreign language articles

201 publications excluded:
95 Other outcomes
73 Other exposures or interventions
17 Diet and physical activity RCTs
13 Observational cohort studies
3 Multimodal RCTs

292 potentially relevant publications on diet, body fatness, physical activity and HRQoL in women with breast cancer

91 publications from 78 RCTs on physical activity and HRQoL included in the systematic review

Figure 1. Flow chart of study selection. HRQoL = health-related quality of life; RCT = randomized controlled trial.
The number of participants in the RCTs ranged from 20 to 573, with a median of 64 participants. Two of the included trials had a crossover design that compared immediate with delayed exercise after completing adjuvant therapy (12, 49), whereas the remaining studies were of a parallel design, comparing the effects of physical activity or exercise with a control group.

Ten studies conducted per-protocol analyses (27, 48, 49, 66, 73, 81, 91, 97, 102, 108), and the remaining studies conducted intention-to-treat analyses. A total of 20 publications were from a pilot or feasibility study (28, 32, 35-40, 44-50, 53, 57, 62, 74, 84, 89, 93, 94, 98, 103). Three pilot studies (4 publications) (32, 35, 93, 94) were followed by a separate complete trial that published results later (13, 34, 82, 83, 90, 92), and the pilot studies and the trials were included as populations were not overlapping. A total of 35 publications (13-15, 26-29, 31, 34, 38-42, 44, 45, 48, 62, 65, 73, 74, 80, 85, 88-94, 99, 102, 103, 110) were from North America, 33 were from Europe (16, 25, 32, 33, 37, 43, 46, 47, 52, 57, 58, 63, 66-70, 76-79, 81-83, 86, 87, 95-98, 101, 104, 105, 107), 9 were from Australia or New Zealand (12, 30, 36, 53, 59-61, 71, 72, 84), 8 were from East Asia or Southeast Asia (49-51, 64, 67, 75, 109, 111), 1 was from India (106), 1 from Iran (100), and 4 from Turkey (54-56, 108).

Risk of Bias of the Studies
Figures 2 and 3 and Supplementary Table 4 (available online) show the summary of the risk of bias assessment across studies and for each RCT investigating the effects of physical activity on HRQoL. Half of the studies were of high risk of bias because the perceived HRQoL outcomes were self-reported by the participants and there were no objective measures to corroborate these patients’ reported outcomes, which could have been influenced by their knowledge of being in the physical activity intervention or not. Because physical activity is generally recognized as beneficial for health, this would likely result in more favorable responses to the outcome assessment and make physical activity appear more beneficial. For the other risk-of-bias domains, approximately 50%-70% were assessed as low risk: 57.7% in randomization process (selection bias); 48.7% in deviations from intended interventions; 70.5% in missing outcome data; and 48.7% in selection of the reported result. The other studies were primarily of some concern (20.5%-50%) or at high risk (3.8%-10.3%) of bias.

Global HRQoL
Physical activity interventions vs control resulted in higher global HRQoL as measured by FACT-B [WMD = 5.50, 95% CI = 2.42 to 8.59; I² = 58%, P_heterogeneity < .001, n = 13] studies (12, 13, 15, 16, 27, 38, 44, 45, 64, 65, 69, 75, 88) and WMCD = 6.40, 95% CI = 4.12 to 8.67; I² = 0%, P_heterogeneity = 0.49, n = 7 (13, 16, 38, 44, 69, 81, 84)], FACT-G [WMD = 4.53, 95% CI = 1.94 to 7.13; I² = 72%, P_heterogeneity < .001, n = 18 (12-15, 31, 38, 43, 46, 47, 59, 65, 69, 74, 83, 85, 91, 109) and WMCD = 3.10, 95% CI = 1.64 to 4.55; I² = 0%, P_heterogeneity = 0.58, n = 8 (31, 38, 69, 81, 83, 85, 93)], and EORTC QLQ-C30 [WMD = 6.78, 95% CI = 2.61 to 10.95; I² = 76.3%, P_heterogeneity < .001, n = 17 (25, 33, 37, 49, 50, 54, 56, 68, 70, 79, 86, 96, 97, 100, 101, 104) and WMCD = 3.64, 95% CI = 0.19 to 7.10; I² = 54.7%, P_heterogeneity = 0.03, n = 8 (37, 50, 60, 79, 95, 96, 105)] (Figure 4; Supplementary Figures 1-6).

General Health Perceptions
Physical activity interventions vs control resulted in higher general health perception scores as measured by the MOS SF-36 and RAND SF-36 on WMDs [WMD = 3.72, 95% CI = 0.74 to 6.70; I² = 71%, P_heterogeneity = 0.01, n = 9 (15, 31, 34, 36, 51, 67, 86, 92)] but not for WMCDs [WMCD = 0.14, 95% CI = -1.57 to 1.85; I² = 0%, P_heterogeneity = 0.93, n = 4 (31, 99, 105)] (Figure 4; Supplementary Figures 7 and 8, available online).
| PMID  | Author          | Year | Experimental | Comparator        | Outcome | Weight |
|-------|-----------------|------|--------------|-------------------|---------|--------|
| 22193780 | Winters-Stone | 2011 | Res (+ impact) | Stretch + Relax | FACT-F  | 1      |
| 21577030 | Mehnert | 2011 | PA UC | SF-36 | 1 |
| 22843897 | Schmidt | 2012 | Res Conven/g415onal PA | EORTC QLQ-C30 | 1 |
| 22169703 | Naumann | 2012 | Aer + Res (+ Coun) | UC + (Coun) | FACT-B | 1 |
| 24771916 | Siedentopf | 2013 | Yoga WL | EORTC QLQ-C30 | 1 |
| 23963636 | Baruth | 2013 | Walk + Coun WL | SF-36 | 1 |
| 25313756 | Murtezani | 2014 | Aer No PA | FACT-G, -B | 1 |
| 27840340 | Shobeiri | 2016 | Aer UC | EORTC QLQ-C30 | 1 |
| 26988367 | Lahart | 2016 | Home PA + Coun UC | FACT-B, -G | 1 |
| 27187092 | Buchan | 2016 | Res Aer FACT-B + 4 | FACT-F | 1 |
| 30340503 | Dieli-Conwright | 2018 | Aer + Res UC | FACT-B, SF-36 | 1 |
| 27161493 | De Luca | 2016 | Aer + Res UC | FACT-G | 1 |
| 25986232 | Cadmus | 2010 | Aer Flex + Relax | EORTC QLQ-C30 | 1 |
| 20734132 | Haines | 2010 | Aer UC FACT-G, -B, SF-36 | 1 |
| 21560021 | Cadmus | 2009 | Aer UC FACT-G, -B, SF-36 | 1 |

Figure 3. Summary of the risk of bias assessment for the individual studies. Aer = aerobic; Ca-rich diet = calcium-rich diet; CBT = cognitive behavioral therapy; CDT = complex decongestive therapy; Coun = counseling; Edu = education; EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30; face = face-to-face intervention; FACT-An = Functional Assessment of Cancer Therapy-Anemia; FACT-B = Functional Assessment of Cancer Therapy-Breast cancer; FACT-B = 4 = Functional Assessment of Cancer Therapy-Breast; FACT-Cog = Functional Assessment of Cancer Therapy-Cognitive; FACT-ES = Functional Assessment of Cancer Therapy-Endocrine Symptoms; FACT-F = Functional Assessment of Cancer Therapy-Fatigue; FACT-G = Functional Assessment of Cancer Therapy-General; FACT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; HIIT = high-intensity interval training; HRQoL = health-related quality of life; PA = physical activity; Rehab = rehabilitation; Relax = relaxation; Res = resistance; SF-12 = Short Form 12; SF-36 = Short Form 36; ST = supportive therapy; tel = over-the-phone intervention; UC = usual care; WL = wait list.
Figure 4. Summary weighted mean differences and weighted mean change differences (95% confidence intervals) for physical activity and different domains of health-related quality of life. Effects that were considered clinically significant are marked with *. CI = confidence interval; EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30; ES = effect size; FACT-B = Functional Assessment of Chronic Illness Therapy–Fatigue; FACT-G = Functional Assessment of Cancer Therapy–General; FACT-B = Functional Assessment of Chronic Illness Therapy–Fatigue; HRQoL = health-related quality of life; MOS/RAND SF-36 = Medical Outcomes Study and RAND Short Form-36; PA = physical activity; WMCD = weighted mean change difference; WMD = weighted mean difference.

### Physical Functioning

Physical activity interventions vs control resulted in higher physical functioning as measured by FACT-B, FACT-B, or FACT-G (WMD = 1.17, 95% CI = 0.58 to 1.75; I² = 44.7%, \( \hat{P} \) heterogeneity = .22, n = 18 (12-16,31,38,39,59,65,69,74,75,83,85,91) and WMD = 1.04, 95% CI = 0.39 to 1.70; I² = 28%, \( \hat{P} \) heterogeneity = .18, n = 10 (16,31,38,69,81,83-85,93)). EORTC QLQ-C30 [WMD = 5.48, 95% CI = 3.27 to 7.68; I² = 50.4%, \( \hat{P} \) heterogeneity = .001, n = 16 (25,33,49,50,58,60,66,79,86,96,97,100,104,106,107)] although not for WMCD, which was 1.92, 95% CI = –0.87 to 4.72; I² = 55%, \( \hat{P} \) heterogeneity = .05, n = 6 (50,60,79,95,96,105]), and MOS SF-36 and RAND SF-36 [WMD = 3.40, 95% CI = 1.16 to 5.65; I² = 72%, \( \hat{P} \) heterogeneity < .001, n = 12 (15,31,34,36,51,52,67,86,88,92,110) but not for WMCD, which was 2.16, 95% CI = –1.42 to 5.75; I² = 78%, \( \hat{P} \) heterogeneity < .001, n = 6 (31,52,99,105,110) (Figure 4; Supplementary Figure 9-14, available online).

### Emotional Functioning

Physical activity intervention vs control resulted in higher emotional functioning as measured by FACT-F, FACT-F, or FACT-G [WMD = 0.74, 95% CI = 0.40 to 1.08; I² = 0%, \( \hat{P} \) heterogeneity = .47, n = 18 (12-16,31,38,39,59,65,69,74,75,83,85,91) and WMD = 0.74, 95% CI = 0.31 to 1.17; I² = 0%, \( \hat{P} \) heterogeneity = .81, n = 10 (16,31,38,69,81,83-85,94)] and EORTC QLQ-C30 [WMD = 6.17, 95% CI = 0.99 to 11.35; I² = 77.8%, \( \hat{P} \) heterogeneity < .001, n = 14 (25,33,49,50,58,60,66,79,86,96,97,100,104,106,107) although not for WMCD, which showed 1.21, 95% CI = –2.33 to 4.75; I² = 51%, \( \hat{P} \) heterogeneity = .09, n = 5 (60,79,95,96,105) (Figure 4; Supplementary Figure 16-19, available online).

### Mental Health Score

Physical activity intervention vs control resulted in higher mental health score as measured by MOS and RAND SF-36 [WMD = 4.42, 95% CI = 2.87 to 5.97; I² = 0%, \( \hat{P} \) heterogeneity = .75, n = 11 (15,31,35,36,51,52,67,86,88,92) but no effect was observed for WMCDs with -1.05, 95% CI = –3.96 to 1.85; I² = 52.8%, \( \hat{P} \) heterogeneity = .91, n = 9 (17,18,25,53,54,68,76,80,110). (Figure 4; Supplementary Figure 15, available online).
P_{heterogeneity} = .07, n = 5 (31,52,99,105) (Figure 4; Supplementary Figures 20 and 21, available online).

Mental Component Summary Score

Physical activity intervention vs control resulted in higher mental component summary score as measured by MOS SF-36 [WMD = 1.70, 95% CI = 0.31 to 3.09; P = 11%, P_{heterogeneity} = .35, n = 7 (15,34,36,52,88,92,102)] (Figure 4; Supplementary Figure 22, available online).

Sensitivity Analyses, Subgroup Analyses, and Publication Bias

Additional analyses were conducted using SMDs, and results were largely consistent with the overall analysis for WMDs (Figure 5). Subgroup and sensitivity analyses were conducted stratified by minimum duration of follow-up, type of physical activity, frequency, duration per session, total duration, intervention time frame, mode of intervention, and type of control (Supplementary Tables 9-20 and Supplementary Figures 23-110, available online). In general, analyses using minimum duration of follow-up showed relatively stronger effects than the main analysis that used the maximum follow-up. Stronger effects were observed for combined aerobic and resistance exercise, and intermediate effects were observed for aerobic exercise and resistance exercise separately, however, some exceptions to this pattern were observed. When using meta-regression analyses, there was a suggestion of between-subgroup heterogeneity (P = .05) with a slightly stronger effect observed between aerobic and resistance exercise combined vs aerobic only and WMDs in physical functioning (FACT-G, FACT-B, FACIT-F) (Supplementary Table 12, available online) and statistically significant between-subgroup heterogeneity (P = .006) with stronger effects for aerobic and resistance exercise combined vs aerobic exercise only for general health perceptions (MOS and RAND SF-36) (Supplementary Table 11, available online).

Subgroup analyses stratified by frequency, duration per session, and total duration showed little evidence of heterogeneity between subgroups with meta-regression analyses (Supplementary Tables 9-20, available online). Some indication of stronger point estimates was also observed for group-based interventions compared with individual-based interventions,
and for interventions after vs during primary adjuvant treatment in several, although not all, analyses; however, the tests for heterogeneity between subgroups were not statistically significant.

There was no indication of publication bias across analyses, except for the analysis on physical functioning as measured by the MOS SF-36 and RAND SF-36, where there was indication of publication bias with Egger test (P = .09) (Supplementary Figures 111-121, available online).

**Adverse Events**

Of the 59 studies that provided information on adverse events, 2 (13,27) reported serious intervention-related adverse events (pelvic stress fracture and foot stress fracture); 20 studies (28,29,38,41,48,53,60,65,66,68-72,81,88,96,103,107,109) reported minor adverse events such as musculoskeletal injuries, chest or muscle pain, dizziness, and treatment-related side effects; and 37 studies (15,30-33,36,37,39,45-47,50,51,54,55,57,59,62,64,67,73-75,78,80,82,84,85,91,99,100,104-106,110,111) reported no adverse events in the intervention and/or control groups (Supplementary Table 21, available online).

**Grading of Evidence**

Evidence was graded according to the predefined CUP Global grading criteria shown in Supplementary Table 2 (available online). There was evidence from multiple RCTs, some observed heterogeneity (but studies were generally consistent regarding the direction of effect), and no indication of publication bias (except for 1 analysis). The strength of the effects was, in general, small to trivial (1 exception was Global HRQoL EORTC QLQ-C30 for which the effect was of medium strength in the analysis of SMDs), but the results were considered clinically significant (small to medium effect or reached minimum important difference) in half of the 34 analyses conducted (Figures 4 and 5; Supplementary Tables 5 and 6, available online), and results were similar in sensitivity analyses using minimum follow-up (Supplementary Tables 7 and 8, available online). Details of the cutoff values that were considered clinically significant for the different tools can be found in Supplementary Table 1 (available online). There was limited evidence for a dose-response effect (Supplementary Tables 9-20, available online). Plausible mechanistic pathways through which physical activity may improve HRQoL include physical activity being associated with improved self-efficacy, which in turn is associated with improvements in health status indicators that are associated with better global QoL (112). Overall, the expert panel judged that there was strong evidence (ie, probable causality) that interventions for increasing physical activity result in improved HRQoL in breast cancer survivors. There was insufficient evidence to draw conclusions on specific domains of QoL or the types and doses of activity for QoL.

**Discussion**

The current systematic review and meta-analysis of 79 RCTs including 14 554 women diagnosed with breast cancer found small, but statistically significant positive effects of physical activity intervention on global HRQoL and physical functioning as measured by FACT-B, FACT-G, EORTC QLQ-C30, and the SF-36 and on the general health perceptions scale of SF-36. Effects were weaker for mental and emotional health. Although the effect sizes were, in general, small, in half of the analyses the results were nevertheless considered clinically significant. There was little evidence of serious adverse events across studies, although some studies reported minor adverse events. There was strong evidence that interventions for increasing physical activity improved QoL in breast cancer survivors with a level of causality that was judged as probable. There was insufficient evidence to draw conclusions regarding specific domains of QoL or the types and doses of activity for QoL.

Our review suggests that the positive effect of physical activity on QoL is more likely to be observed when the intervention is initiated after primary adjuvant treatment rather than during treatment when measured by the FACT (but not by the EORTC QLQ-C30), but more research is needed regarding this question. A possible explanation is that women undergoing cancer treatment may be affected by side effects related to breast cancer treatment including fatigue, pain, and peripheral neuropathy (113), which could interfere with the adherence to physical activity interventions during treatment and attenuate any impact on QoL. Also, the EORTC QLQ-C30 is designed to assess QoL related to chronic treatment side effects (114), thus it may be less suitable for capturing short-term QoL leading to an underestimation and increased variability of the underlying effect when considered after treatment. Our results are supported by 2 Cochrane Systematic Reviews focusing on exercise interventions during (115) and after treatment (7).

We also observed somewhat greater effects in group-based interventions compared with individual-based or mixed interventions, however, the evidence base was limited by the low number of studies and limited number of participants. Although the current review was structured to capture the distinct effect of physical activity disentangled from other types of interventions such as those that were multimodal, we cannot exclude the possibility that other aspects of social support may interplay with the effect of physical activity in group-based interventions. This hypothesis—that group-based interventions may have additional postulated benefits via indirect effects involving social support and group dynamics like comradeship of breast cancer survivors—has been previously examined (116,117) and showed no difference in results when compared with individual-based interventions. However, the possibility that the design of the group-based interventions may not have involved sufficient social interaction to show a difference in results could not be excluded.

With respect to specific types of physical activity, a combined aerobic and resistance intervention seemed to result in higher QoL improvement compared with other types of activity, although the number of RCTs in each subgroup was low. The effects of resistance-only and aerobic-only interventions were generally lower in magnitude. Including walking interventions in the aerobic exercise group as a sensitivity analysis did not materially change the results. The effects of yoga in all QoL scales and subscales were either statistically nonsignificant or not clinically meaningful. A previous Cochrane review for yoga also showed only small, short-term benefits compared with no exercise on overall QoL (6). Few studies were published on other types of physical activity, such as dancing, stretching, Nia, Tai Chi or Qigong. Although some of the included studies focused primarily on activities that may be more pertinent to specific treatment goals and outcomes that were not considered in the current review (eg, resistance training for lymphedema or walking for aromatase inhibitor–associated arthralgia) (30,36,50,57,67,85), these studies were few and are unlikely to have had a major impact on the overall findings. Further studies...
are needed to clarify to what extent specific types of activity are particularly beneficial for various QoL outcomes. Future work within the CUP Global will include reviewing the impact of other exposures, such as diet, nutrition, and body weight, on QoL outcomes. This will enable WCRF International and the national entities (AICR, WCRF UK, Wereld Kanker Onderzoek Fonds) to expand their recommendations for improving QoL outcomes in this group.

In this comprehensive systematic review, we summarized the available evidence from RCTs regarding the impact of physical activity on QoL in women with breast cancer. The structure of the research question allowed for identifying and disentangling the effect of physical activity on QoL. We specifically focused on the independent effect of physical activity regimens; evidence from multimodal interventions that included physical activity were not evaluated as the component-specific effects could not be estimated. Furthermore, the considerable number of included studies allowed for a comprehensive evaluation of several validated tools of QoL measurement and their subscales. Although different tools for QoL assessment emphasize different aspects of QoL (e.g., FACT-G and EORTC QLQ-C30 place more emphasis on symptoms and less on physical functioning compared with SF-36 [17]), results were similar when different tools for QoL assessment were considered. This might suggest that physical activity could have a beneficial impact across a range of QoL components. Other published reviews further support the beneficial effects of any type of exercise (118) or of specific types of exercise (119) on QoL in women with breast cancer, and an individual-participant meta-analysis of 34 RCTs (70% of participants were breast cancer survivors) also found a small but significant effect of exercise on QoL and physical function ($z$ score = 0.15, 95% CI = 0.10 to 0.20, and $z$ score = 0.18, 95% CI = 0.13 to 0.23, respectively) (120).

Despite the large evidence base, most of the identified studies were relatively small (the majority of the RCTs had less than 100 participants), and several studies may therefore individually have had insufficient power to detect significant effects. When change scores between recruitment and end of follow-up were considered, less pronounced effects were observed at more distal time points. One potential explanation could be that baseline values were accounted for in the mean change scores. Furthermore, the weighted mean change score may be a more appropriate measure of effect compared with the mean difference of final scores, because more than 70% of the included trials had less than 100 participants and the baseline values were not always balanced between groups. Other explanations for this discrepancy could be that the analysis of WMDs only included about half or less the number of studies that were included in the analysis of WMDs, providing less statistical power to detect relations, or it could be because of response shift, which involves changes in internal standards, values, and the conceptualization of QoL related to a breast cancer diagnosis (121).

The accumulated evidence from RCTs had a high risk of bias overall, based on the Cochrane Revised Cochrane Risk-of-Bias tool for Randomized trials, but this can be mostly attributed to potential biases in measurement of the outcome as only patient-reported outcomes were assessed and the participants could not be blinded to the intervention. The other bias domains showed substantially lower risk of bias. Despite being self-reported, the tools assessed in this review have been validated and were also relevant to the population of interest, with some, such as the FACT-B, being specifically tailored to breast cancer survivors (122). A varying degree of heterogeneity across the analyses was observed, which could potentially limit the generalizability of the results from some of the analyses. Although we did perform subgroup and sensitivity analyses based on several prespecified factors, such as type of physical activity, frequency, duration, mode of intervention, time frame of intervention, type of control, and on the studies’ minimum follow-up, other potentially relevant modifiers such as tumor stage at diagnosis, age, or comorbidities could not be evaluated. However, across the numerous analyses that were conducted, the majority of the studies showed either a beneficial effect or no significant relation, and there were few studies that showed estimates in the direction of an adverse effect. Some studies may have been missed from our review, however, the literature search was comprehensive and supplemented by hand searches of relevant reviews and should have identified the majority of the relevant studies. In general, we did not find evidence of publication bias by visually inspecting the funnel plots or based on Egger regression test, but the number of studies included in some of the meta-analyses was relatively small. The only exception was for SF-36 physical function score where there was evidence of an inflated summary estimate because of small study effects.

There is strong evidence that interventions for increasing physical activity result in improved QoL in breast cancer survivors with a level of causality that was judged as probable. There was insufficient evidence to draw conclusions regarding different domains of QoL (e.g., physical, global, emotional functioning) or for specific types, combinations, or doses of activity. It is therefore recommended that breast cancer survivors should be encouraged to be physically active. In the absence of strong evidence for more specific recommendations unique to breast cancer survivors, they should follow the general population national guidelines for physical activity, under the guidance of their healthcare team. Additional research should focus on larger, well-conducted studies on the relationship between dose of physical activity (including frequency, duration, and intensity) and type of physical activity and QoL.

**Funding**

This work was funded by the World Cancer Research Fund network of charities (American Institute for Cancer Research [AICR], World Cancer Research Fund [UK], Wereld Kanker Onderzoek Fonds [WKOF]). Support was provided by the American Cancer Society (CRP-19-175-06-COUN) to Wendy Demark-Wahnefried, and Anne McTiernan was supported by the Breast Cancer Research Foundation grants BCRF-20-107 and BCRF-21-107.

**Notes**

**Role of the funder:** The funders of this study had no role in the decisions about the design and conduct of the study; collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.

**Disclosures:** Dagfinn Aune, Georgios Markozannes, Rita Vieira, Katia Balducci, Margarita Cariolou, Konstantinos K Tsilidis, and Doris S.M. Chan are supported by the World Cancer Research Fund network of charities. Teresa Norat, Leila Abar, and Neesha Nanu were previously supported by the World Cancer Research Fund.
Fund network of charities. All authors have no conflict of interest.

**Author contributions:** Conceptualization: TN, DSMC, KKT. Data curation: YOA, DA, GM, DSMC. Formal analysis: DA, GM. Funding acquisition: TN, DSMC, KKT. Investigation: DSCMC, NN, LA, KB, MC, RV, DA, GM. Methodology: TN, DSMC, KKT, GV, AMT, SC, WDW, VL, GM, DCG. Project administration: DSCMC, KKT, KA, NGT, HC, DK, DMMG, PM, MW. Software: YOA. Supervision: KKT, DSCMC, GV, WDW, AMT, SKC, ELG, EK, AAJ, MJG, VL, ER, DCG. Writing—original draft: DA, GM. Writing—review & editing: DA, GM, LA, KB, MC, NN, RV, YOA, DCG, SKC, ELG, MJG, AAJ, EK, VL, AMT, ER, KA, NTB, HC, DK, DMMG, PM, MW, GV, WDW, TN, KKT, DSCMC.

**Acknowledgements:** We thank Dr Martijn Bours (Maastricht University) for his expert opinion on the review protocol. We also acknowledge the input of Isobel Bandurek and Susannah Brown as past CUP Secretariat members.

**Disclaimer:** The views expressed in this review are the opinions of the authors. They may differ from those in future updates of the evidence related to food, nutrition, physical activity, and quality of life in breast cancer survivors. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.

**Prior presentations:** These results have been presented as an abstract at the National Cancer Research Institute Cancer Conference in November 2021 in London, United Kingdom.

**Data Availability**

The data underlying this article are available in the article itself and in its online Supplementary Material.

**References**

1. World Health Organization. WHO Definition of Health. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference. New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 States and entered into force on 7 April 1948. https://www.who.int/about/governance/constitutions#:~:text=Health%20is%20a%20state%20of%20complete%20physical%20and%20mental%20well-being%20and%20not%,conditions%20of%20illness%20or%20disease%20or%20disability.%20Accessed%20November%2012, 2022.
2. De Salvo KB, Blosser N, Reynolds K, He J, Munster P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med. 2006;21(3):267-275.
3. Egplem M, Zheng Y, Zheng W, et al. Quality of life after breast cancer diagnosis and survival. J Clin Oncol. 2011;29(4):406-412.
4. O’Mara AM, Denicoff AM. Health related quality of life in NCI-sponsored cancer treatment trials. Semin Oncol Nurs. 2010;26(4):67-78.
5. Lipsett A, Barretti S, Haruna F, Mustian K, O'Donovan A. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: a systematic review and meta-analysis. Breast. 2017;32:144-155.
6. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 2017;1:C0010802.
7. Lahart BM, Metsois GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;1:C0012992.
8. Soares Falcetta F, de Araujo Vianna Trassel H, et al. Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2018;170(3):455-476.
9. Spieck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):87-100.
10. Mishra SJ, Scherer RW, Geihe PM. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;2012:CD007566.
11. Baumann FT, Reike A, Hallek M, Wiskemann J, Reimer V. Does exercise have a preventive effect on secondary lymphedema in breast cancer patients following local treatment—a systematic review. Breast Care (Basel). 2018;13(5):380-385.
12. Milne HM, Wallman KE, Gordon S, Courneya KS. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2015;154(1):109-119.
13. Rogers LQ, Courneya KS, Anton PM, et al. Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobnic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled trial. Breast Cancer Res Treat. 2015;149(1):109-119.
14. Model A, Shah C, Wylie-Rosett J, et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J Clin Oncol. 2007;25(28):4387-4395.
15. Dei-Conwright CM, Courneya KS, Demark-Wahnefried W, et al. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. Breast Cancer Res. 2018;20(1):124.
16. Kramer H, Rabilser S, Lauche R, Kummel S, Dobos G. Yoga and meditation for menopausal symptoms in breast cancer survivors: a randomized controlled trial. Cancer. 2015;121(13):2175-2184.
17. Ferrans CE. Differences in what quality-of-life instruments measure. J Natl Cancer Inst Monogr. 2007;2007(37):22-26.
18. Imperial College Continuous Update Project team. Protocol for the data collection and systematic literature reviews on the role of diet, body fatness and physical activity on health-related quality of life after diagnosis of breast cancer: https://www.imperial.ac.uk/school-public-health/epidemiology-and-biostatistics/research/cancer-and-nutritional-epidemiology/global-cancer-update-programme/. Accessed November 01, 2022.
19. Moher D, Liberati A, Tetzlaff J, Altman DG; for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
20. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:k4308.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986(3):177-188.
22. Higgins JP, Green S. Chapter 7: Selecting studies and collecting data. In: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Updated March 2011. https://handbook-5-1.cochrane.org/front_page.htm. Accessed August 18, 2020.
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1599-1558.
24. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Stat Med. 1997;15(4):279-289.
25. Ammitzbøll G, Kristina Kjær T, Johannsen C, et al. Effect of progressive resistance training on health-related quality of life in the first year after breast cancer surgery-results from a randomized controlled trial. Acta Oncol. 2019;58(5):665-672.
26. An KY, Morrelli AR, Kang DW, et al. Effects of exercise dose and type during breast cancer chemotherapy on longer-term patient-reported outcomes and health-related fitness: a randomized controlled trial. Int J Cancer. 2020;146(1):150-160.
27. Anderson RT, Kimmick GG, McCoy TP, et al. A randomized trial of exercise on well-being and function following breast cancer surgery: the RESTORE trial. J Cancer Surviv. 2012;6(2):172-181.
28. Baruth M, Wilcox S, Der AC, Heiny S. Effects of home-based walking on quality of life and fatigue outcomes in early stage breast cancer survivors: a 12-week pilot study. J Phys Act Health. 2015;12(suppl 1):S110-S118.
29. Brown JC, Schmitz KH. Weight lifting and physical function among survivors of breast cancer: a post hoc analysis of a randomized controlled trial. J Clin Oncol. 2015;33(19):2184-2189.
30. Buchanan J, Janda M, Box R, Schmitz K, Hayes S. A randomized trial on the effect of exercise mode on breast cancer-related lymphedema. Med Sci Sports Exerc. 2016;48(10):1866-1874.
31. Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML. Exercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trials. Psychol Oncol. 2009;18(4):343-352.
32. Campbell A, Mutrie N, White F, McGuire F, Kearney N. A pilot study of a supervised group exercise programme as a rehabilitation treatment for women with breast cancer receiving adjuvant treatment. Eur J Oncol Nurs. 2005;9(1):56-63.
33. Ceiseko R, Eglitis J, Srebnijs A, et al. The impact of maximal strength training on quality of life among women with breast cancer undergoing radiotherapy. J Clin Oncol. 2014;32(10):1058-1065.
34. Chandwani KD, Perkins G, Nagendra HR, et al. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol. 2014;32(10):1058-1065.
35. Chandwani KD, Thornton B, Perkins GH, et al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol. 2010;8(2):43-55.
Cornette T, Pumpa K, Galvao DA, et al. Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomized controlled trial. J Cancer Surviv. 2013;7(3):413-424.

Corkette T, Vincent F, Mandigout S, et al. Effects of home-based exercise training on VO2 in breast cancer patients under adjuvant or neoadjuvant chemotherapy (SAPA): a randomized controlled trial. Eur J Phys Rehabil Med. 2015;52(2):223-232.

Courneya KS, Mackey JR, Bell CJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003;21(9):1660-1668.

Courneya KS, McKenzie DC, Mackey JR, et al. Effects of exercise dose and type during breast cancer chemotherapy: multcenter randomized trial. J Natl Cancer Inst. 2013;105(23):1821-1832.

Courneya KS, McKenzie DC, Mackey JR, et al. Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer. 2008;112(8):1845-1853.

Courneya KS, Segal RJ, Gelinas K. Six month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. Cancer Epidemic Biomarkers Prev. 2007;16(12):2572-2579.

Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multcenter randomized controlled trial. J Clin Oncol. 2007;25(28):4396-4404.

Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roaife A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 2007;25(13):1713-1721.

Danhauer SC, Griffin LP, Avis NE, et al. Feasibility of implementing a community-based randomized trial of yoga for women undergoing chemotherapy for breast cancer. J Community Support Oncol. 2015;13(4):129-147.

Danhauer SC, Miller SL, Russell GB, et al. Restorative yoga for women with breast cancer: findings from a randomized pilot study. Psychonol. 2009;18(4):360-368.

De Luca V, Minganti C, Borrione F, et al. Effects of concurrent aerobic and strength training on breast cancer survivors: a pilot study. Public Health. 2016;136:126-132.

Demark-Wahnefried W, Case LD, Blackwell K, et al. Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. Clin Breast Cancer. 2008;8(1):70-79.

Desbiens C, Filion M, Brien MC, Hogue JC, LaFlamme C, Lemieux J. Impact of physical activity in group versus individual physical activity on fatigue in patients with breast cancer: a pilot study. Breast. 2017;35:8-13.

De J, Cho Y, Jeon J. Effects of a 4-week multimedical rehabilitation program on quality of life, cardiopulmonary function, and fatigue in breast cancer patients. J Breast Cancer. 2015;18(1):87-96.

De J, Kim W, Cho YK, et al. Effects of resistance exercises and complex decongestive therapy on arm function and muscular strength in breast cancer related lymphedema. Lymphology. 2015;48(4):184-196.

Dong X, Yi X, Gao D, et al. The effects of the combined exercise intervention based on internet and social media software (CEIBISMS) on quality of life, body image, and health-related quality of life among breast cancer patients with breast cancer-related lymphedema. J Clin Oncol. 2010;28(34):4638-4645.

Eakin EG, Lawler SP, Winkler EA, Hayes SC. A randomized trial of a web-based adaptive exercise program on self-esteem and quality of life among breast cancer patients on adjuvant chemotherapy. J Pain Symptom Manage. 2010;9(12):1844-1848.

Eckert KA, Rabinbinder S, Lauchle R, et al. The effects of yoga and self-esteem on menstrual symptoms and quality of life in breast cancer survivors—a secondary analysis of a randomized controlled trial. Maturitas. 2017;105:95-99.

Lahart IM, Mettias GS, Nevill AM, Kitas GD, Carmichael AR. Randomised controlled trial of a home-based physical activity intervention in breast cancer survivors. BMC Cancer. 2016;16:234.

Landry S, Charles G, Pointreau Y, Bourgeois H, Boyay S. Influence of an adapted physical activity group on self-esteem and quality of life of breast cancer patients after mastectomy. Oncology. 2018;95(3):188-191.

Lee TS, Kilbrath SL, Reifshaume KM, Pendlebury SC, Beith JM, Lee M J. Fectoral stretching program for women undergoing radiotherapy for breast cancer. Breast Cancer Res Treat. 2007;102(3):319-321.

Lee SA, Kang KY, Kim YD, et al. Effects of a scapula-oriented shoulder exercise programme on upper limb dysfunction in breast cancer survivors: a randomized controlled pilot trial. Clin Rehabil. 2010;24(7):600-613.

Ligibel JA, Goodwin-Hurder A, Shockro L, et al. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer. 2016;122(8):1169-1177.

Littman AJ, Bertram LC, Ceballos R, et al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures. Support Care Cancer. 2012;20(2):265-277.

Loh SY, Lee SY, Murray L. The Kuala Lumpur Gigong trial for women in the cancer survivorship phase—efficacy of a three-arm RCT to improve QOL. Asian Pac J Cancer Prev. 2014;15(9):8127-8134.

Lotzke D, Wiedemann F, Rodrigues RD, et al. Iyengar-Yoga compared to exercise as a therapeutic intervention during (neo)adjuvant therapy in women in stage I-III breast cancer: health-related quality of life, mindfulness, spirituality, satisfaction, and cancer-related fatigue. Evid Based Complement Alternat Med. 2016;2016:5391816.

Mehnehrt A, Veers S, Howaldt D, Braumann EM, Koch U, Schulz KH. Effects of a physical exercise rehabilitation group program on anxiety, depression, body image, and health-related quality of life among breast cancer patients. Oncology. 2011;34(5):248-253.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial with economic evaluation. Breast Cancer Res Treat. 2010;124(1):163-175.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.

Mijwel S, Jervaeus A, Bolam KA, et al. Randomized controlled trial. Eur J Cancer Care (Engl). 2016;25(5):784-794.
